Leading Asia-Pacific CRO and Medidata partner to enable smarter, faster drug development
Novotech adopts Medidata Rave EDC and Coder to support clinical trials
- New partnership is an example of the collaboration needed in the APAC biotech sector to manage the growing complexity of clinical trials
SYDNEY – Jan. 17, 2019 – Medidata (NASDAQ: MDSO) today announced a partnership with Asia-Pacific clinical research organisation (CRO), Novotech.
To help facilitate smarter, faster drug development across the Asia-Pacific region, Novotech will leverage Medidata products as part of its clinical trial service offering, including:
- Rave EDC: the world’s leading solution for capturing, managing and reporting patient data
- Rave Coder: cloud application that streamlines and centralises medical coding
CEO of Novotech, John Moller, said, “We’re excited to partner with Medidata to support quality clinical research throughout the Asia-Pacific region.”
“Novotech has always invested heavily in the latest technology to provide our clients better data visibility for improved decision-making. By partnering with Medidata, we will together help sponsors deliver more efficient and effective trials,” he concluded.
As Asia-Pacific becomes an important destination for clinical trials, advanced IT is needed to extract the true value of the data arising from these studies. The Novotech and Medidata partnership will help sponsors ensure trials are progressing in an efficient manner, reducing the overall trial timeline and improving the patient experience.
Medidata vice president, field operations, APeJ, Edwin Ng, said: “The Asia-Pacific region is on track to establish itself as a clinical trials leader, and we’re excited to deliver the technology innovation needed to accelerate this goal.”
“Partnering with Novotech will support us as we navigate the complex Asia-Pacific regulatory landscape and introduce new technologies. This will ensure we’re focusing on enhancing the quality of clinical data and the overall patient experience,” he concluded.
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO), with on-the-ground operations in Australia, New Zealand, South Korea, China, Taiwan, Philippines, Hong Kong, Singapore Malaysia, Thailand and India. Novotech also has worldwide reach through the company's network of strategic partners. With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets.
Novotech recently acquired Australasian specialist CRO Clinical Network Services (CNS) as part of a mutual mission to expand services to biopharma for early phase product development and clinical research, through to later phase regional and global trials.
More information on Novotech is available at: https://novotech-cro.com/welcome
For all media enquiries, please contact:
Susan Fitzpatrick-Napier, Novotech
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427